DOVATO has a
well-established
safety profile[1]

DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.[1]

DOVATO IS GENERALLY WELL-TOLERATED[1]

The frequency of adverse reactions observed in clinical studies and post-marketing experiences is listed below.[1]

Proven efficacy from diagnosis[1–3]

Explore efficacy of DOVATO

The confidence of a proven high barrier to resistance[1–3]

Discover barrier to resistance

Fewer clinically significant DDIs with non-ARVs vs. other single-tablet regimens including BIC/FTC/TAF, as reported in EACS 2025 guidelines§,[4]

View DDI profile

* Particularly in patients with a pre-existing history of depression or psychiatric illness.[1]
†This adverse reaction was identified through post-marketing surveillance for dolutegravir in combination with other ARVs. The frequency category of rare was estimated based on post-marketing reports.[1]
‡In combination with increased transaminases.[1]
||Reversible sideroblastic anaemia has been reported with dolutegravir-containing regimens. The contribution of dolutegravir in these cases is unclear.[1]
§As defined in EACS guidelines. Includes the most common and clinically relevant interactions with 43 non-ARV medications. Included in EACS guidelines, as commonly co-prescribed or of particular clinical relevance. Original data source: University of Liverpool HIV drug interaction data.[4] EACS guidelines state that no additional DDIs are expected when 3TC is added to other ARTs including DTG.[1,4]

ALT, alanine aminotransferase; ARV, antiretroviral; AST, aspartate aminotransferase; BIC, bictegravir; CPK, creatine phosphokinase; DDI, drug-drug interaction; FTC, emtricitabine; TAF, tenofovir alafenamide.

References:

  1. DOVATO (dolutegravir/lamivudine) Summary of Product Characteristics (SmPC)
  2. Figueroa M et al. Clin Infect Dis 2025. https://doi.org/10.1093/cid/ciaf415. [Epub ahead of print].
  3. Cahn P et al. AIDS 2022; 36(1): 39–48.
  4. European AIDS Clinical Society (EACS) Guidelines. Version 13.0. October 2025.

PM-GB-DLL-WCNT-250008 | February 2026

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.